DRRX

DUR-928

Alcoholic Hepatitis (AH)

Phase 2

Exp Date

TBD

Amp Volatility Score

N/A

Catalyst Info & Data Links

TITLE: DUR-928 for Alcoholic Hepatitis (AH) - Phase 2 

  • ClinicalTrials.gov (NCT04563026): A Phase 2b Study in Subjects With Alcoholic Hepatitis to Evaluate Safety and Efficacy of DUR-928 Treatment (AHFIRM)

WHAT IS THE NEXT CATALYST EVENT?

  • Dosing First Patients/Readout in the Future 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • TBD (Latest Quarterly Call says anyday) 


PRIOR DATA

PRESS RELEASES

MECHANISM OF ACTION

  • DURECT's lead drug candidate, DUR-928, is an endogenous sulfated oxysterol and an epigenetic regulator. It represents a new class of therapeutics with a unique mechanism of action. DUR-928 epigenetically modulates the expression of multiple clusters of master genes that are involved in many important cell signaling pathways, through which it stabilizes mitochondria, reduces lipotoxicity, regulates inflammatory or stress responses, and promotes cell survival.

Updated by JM 

DRRX, Durect, Alcoholic Hepatitis (AH), DUR-928

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon